{"id":50453,"date":"2022-11-03T17:02:31","date_gmt":"2022-11-03T16:02:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/"},"modified":"2022-11-03T17:02:31","modified_gmt":"2022-11-03T16:02:31","slug":"atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/","title":{"rendered":"AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies"},"content":{"rendered":"
\n

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc.<\/a> has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System. Building on acute data from the PASS PULL EV-ICD Study (n=18) completed in Q1-2022, the Sensing and Defibrillation with a Commercially Available ICD coupled with a Parasternal Extravascular Lead (SECURE EV) study (n=18) followed subjects with an AtaCor Medical EV-ICD lead connected to a commercially available ICD pulse generator for up to 3 months. Data from all 36 clinical study patients will be presented as a Late-Breaking Clinical Trial at the Asia Pacific Heart Rhythm Society (APHRS<\/a>) Scientific Session 2022 in Singapore on November 20, 2022.\n<\/p>\n

<\/a><\/p>\n

\nAtaCor Medical\u2019s novel EV-ICD lead is being designed to provide both shock and pacing therapies to treat life-threatening tachyarrhythmias when connected to commercially available ICD pulse generators. The lead is designed to be inserted at the left sternal margin through a rib space above the heart, leaving the heart completely untouched.\n<\/p>\n

\nBuilding upon the acute data previously collected in the PASS PULL EV-ICD study, the SECURE EV study evaluated chronic sensing and defibrillation with AtaCor\u2019s EV-ICD lead while connected to a commercially available ICD pulse generator. All SECURE EV subjects received a concomitant transvenous ICD to allow direct comparison of sensing and detection between the traditional transvenous ICD System and an AtaCor Medical EV-ICD System.\n<\/p>\n

\n\u201cWe are excited to build upon our acute data with completion of 3 month follow-up visits in our first chronic defibrillation study,\u201d remarked Rick Sanghera, AtaCor Medical\u2019s CEO. \u201cOur goal is to revolutionize the entire cardiac rhythm management industry, and this study is a significant advancement on that road.\u201d\n<\/p>\n

\nJohan Aasbo, D.O., an investigator in the study, added, \u201cThe goal of AtaCor Medical\u2019s EV-ICD lead and delivery system is to offer a novel, minimally invasive, and time efficient lead implantation modality built to connect to commercially available transvenous ICD pulse generators. It was my privilege to participate in the implantation, gathering, and analysis of the system’s initial 90-day performance evaluation. This research will serve as the foundation for longer implant duration studies. The ultimate goal will be to evaluate the AtaCor Medical EV-ICD System as a viable option for sudden cardiac death risk mitigation.\u201d\n<\/p>\n

\nAbout AtaCor Medical, Inc.<\/b>\n<\/p>\n

\nEstablished in 2014, AtaCor Medical is transforming cardiac pacing and defibrillation. AtaCor Medical\u2019s extracardiac pacing lead is designed to be inserted between the ribs and pericardium without the need for medical imaging, allowing for faster, less-invasive therapy delivery. AtaCor Medical\u2019s EV-ICD lead is inserted in a similar location and is being designed to offer permanent defibrillation and pacing therapies for the treatment of life-threatening tachyarrhythmias and bradycardia.\n<\/p>\n

\nAtaCor Medical\u2019s management team<\/a> is comprised of seasoned experts from within the implantable cardiac device and electrophysiology fields, bringing over 80 years of combined experience to the company and its products. Current investors include Broadview Ventures, Hatteras Venture Partners, and Catalyst Health Ventures. At this time, AtaCor Medical\u2019s extracardiac pacing and EV-ICD lead systems are under development, and not yet approved for sale in any geography.\n<\/p>\n

\nFor more information, please visit www.atacor.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAtaCor Medical, Inc.
\n
Rick Sanghera
\n
press@atacor.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System. Building on acute data from the PASS PULL EV-ICD Study (n=18) completed in Q1-2022, the Sensing and Defibrillation with a Commercially Available ICD coupled with a Parasternal Extravascular Lead (SECURE EV) … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50453","6":"format-standard","7":"category-industry"},"yoast_head":"\nAtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System. Building on acute data from the PASS PULL EV-ICD Study (n=18) completed in Q1-2022, the Sensing and Defibrillation with a Commercially Available ICD coupled with a Parasternal Extravascular Lead (SECURE EV) ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-03T16:02:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221103005645\/en\/787645\/21\/AtaCorMedical.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies\",\"datePublished\":\"2022-11-03T16:02:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/\"},\"wordCount\":544,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005645\\\/en\\\/787645\\\/21\\\/AtaCorMedical.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/\",\"name\":\"AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005645\\\/en\\\/787645\\\/21\\\/AtaCorMedical.jpg\",\"datePublished\":\"2022-11-03T16:02:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005645\\\/en\\\/787645\\\/21\\\/AtaCorMedical.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221103005645\\\/en\\\/787645\\\/21\\\/AtaCorMedical.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/","og_locale":"en_US","og_type":"article","og_title":"AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies - Pharma Trend","og_description":"SAN CLEMENTE, Calif.–(BUSINESS WIRE)–AtaCor Medical, Inc. has announced completion of its second human clinical study of the Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Lead System. Building on acute data from the PASS PULL EV-ICD Study (n=18) completed in Q1-2022, the Sensing and Defibrillation with a Commercially Available ICD coupled with a Parasternal Extravascular Lead (SECURE EV) ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-03T16:02:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221103005645\/en\/787645\/21\/AtaCorMedical.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies","datePublished":"2022-11-03T16:02:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/"},"wordCount":544,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103005645\/en\/787645\/21\/AtaCorMedical.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/","url":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/","name":"AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221103005645\/en\/787645\/21\/AtaCorMedical.jpg","datePublished":"2022-11-03T16:02:31+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221103005645\/en\/787645\/21\/AtaCorMedical.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221103005645\/en\/787645\/21\/AtaCorMedical.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/atacor-medical-to-present-acute-and-3-month-results-from-extravascular-implantable-cardioverter-defibrillator-ev-icd-studies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"AtaCor Medical to Present Acute and 3 Month Results from Extravascular Implantable Cardioverter Defibrillator (EV-ICD) Studies"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50453"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50453\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}